{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T08:19:26Z","timestamp":1767860366927,"version":"3.49.0"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,3,16]],"date-time":"2021-03-16T00:00:00Z","timestamp":1615852800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell. Infect. Microbiol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Convalescent plasma (CP) transfusion is considered to be the priority therapeutic option for COVID-19 inpatients when no specific drugs are available for emerging infections. An alternative, simple, and sensitive method is urgently needed for clinical use to detect neutralization activity of the CP to avoid the use of inconvenient micro-neutralization assay.<\/jats:p><\/jats:sec><jats:sec><jats:title>Method<\/jats:title><jats:p>This study aims to explore optimal index in predicting the COVID-19 CP neutralization activity (neutralizing antibody titers, NAb titers) in an indirect ELISA format. Fifty-seven COVID-19-recovered patients plasma samples were subjected to anti-SARS-CoV-2 RBD, S1, and N protein IgG antibody by indirect ELISA.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>ELISA-RBD exhibited high specificity (96.2%) and ELISA-N had high sensitivity (100%); while ELISA-S1 had low sensitivity (86.0%) and specificity (73.1%). Furthermore, ELISA-RBD IgG titers and pseudovirus-based NAb titers correlated significantly, with R<jats:sup>2<\/jats:sup> of 0.2564 (P &amp;lt; 0.0001).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>ELISA-RBD could be a substitute for the neutralization assay in resource-limited situations to screen potential plasma donors for further plasma infusion therapy.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fcimb.2021.650487","type":"journal-article","created":{"date-parts":[[2021,3,16]],"date-time":"2021-03-16T06:50:33Z","timestamp":1615877433000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Predictive Analysis of the Neutralization Activity in Convalescent Plasmas From COVID-19 Recovered Patients in Zhejiang Province, China, January-March, 2020"],"prefix":"10.3389","volume":"11","author":[{"given":"Yajie","family":"Yuan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zi","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongjun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meng","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haojie","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xunhui","family":"Zhuo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fei","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaojun","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guoqing","family":"Ying","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaowei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingming","family":"Kong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaohong","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hangjun","family":"Lv","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,3,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"m3939","DOI":"10.1136\/bmj.m3939","article-title":"\u201cConvalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial).\u201d","volume":"371","author":"Agarwal","year":"2020","journal-title":"BMJ"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1038\/s41591-020-0913-5","article-title":"\u201cA serological assay to detect SARS-CoV-2 seroconversion in humans.\u201d","volume":"26","author":"Amanat","year":"2020","journal-title":"Nat. Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"2757","DOI":"10.1172\/JCI138745","article-title":"Deployment of convalescent plasma for the prevention and treatment of COVID-19","volume":"130","author":"Bloch","year":"2020","journal-title":"J. Clin. Invest."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1093\/infdis\/jiaa505","article-title":"\u201cSevere Acute Respiratory Syndrome Coronavirus 2 Neutralizing Antibody Titers in Convalescent Plasma and Recipients in New Mexico: An Open Treatment Study in Patients With Coronavirus Disease 2019.\u201d","volume":"222","author":"Bradfute","year":"2020","journal-title":"J. Infect. Dis."},{"key":"B5","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.chom.2020.06.021","article-title":"\u201cNeutralizing Antibody and Soluble ACE2 Inhibition of a Replication-Competent VSV-SARS-CoV-2 and a Clinical Isolate of SARS-CoV-2.\u201d","volume":"28","author":"Case","year":"2020","journal-title":"Cell Host Microbe"},{"key":"B6","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1111\/vox.12968","article-title":"Early experience with convalescent plasma as immunotherapy for COVID-19 in China: Knowns and unknowns","volume":"115","author":"Chen","year":"2020","journal-title":"Vox. Sang."},{"key":"B7","doi-asserted-by":"publisher","first-page":"11709","DOI":"10.1074\/jbc.RA118.001897","article-title":"\u201cMiddle East respiratory syndrome coronavirus and bat coronavirus HKU9 both can utilize GRP78 for attachment onto host cells.\u201d","volume":"293","author":"Chu","year":"2018","journal-title":"J. Biol. Chem."},{"key":"B8","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.3390\/jcm9072084","article-title":"\u201cSARS-CoV-2: Repurposed Drugs and Novel Therapeutic Approaches-Insights into Chemical Structure-Biological Activity and Toxicological Screening.\u201d","volume":"9","author":"Dehelean","year":"2020","journal-title":"J. Clin. Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1111\/j.1462-5822.2006.00698.x","article-title":"\u201cChanges in nucleolar morphology and proteins during infection with the coronavirus infectious bronchitis virus.\u201d","volume":"8","author":"Dove","year":"2006","journal-title":"Cell Microbiol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1002\/eji.202048970","article-title":"\u201cSeroprevalence of anti-SARS-CoV-2 antibodies in COVID-19 patients and healthy volunteers up to 6 months post disease onset.\u201d","volume":"50","author":"Figueiredo-Campos","year":"2020","journal-title":"Eur. J. Immunol."},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.579250","article-title":"\u201cProgress and Pitfalls in the Quest for Effective SARS-CoV-2 (COVID-19) Vaccines.\u201d","volume":"11","author":"Flanagan","year":"2020","journal-title":"Front. Immunol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.ejim.2020.05.019","article-title":"\u201cWhy should we use convalescent plasma for COVID-19?\u201d","volume":"77","author":"Franchini","year":"2020","journal-title":"Eur. J. Intern. Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1002\/eji.202048715","article-title":"\u201cLIPS method for the detection of SARS-CoV-2 antibodies to spike and nucleocapsid proteins.\u201d","volume":"50","author":"Haljasmagi","year":"2020","journal-title":"Eur. J. Immunol."},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.01196","article-title":"\u201cCOVID-19 Therapeutic Options Under Investigation.\u201d","volume":"11","author":"Kaddoura","year":"2020","journal-title":"Front. Pharmacol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1007\/s10096-017-3043-3","article-title":"\u201cSuggested new breakpoints of anti-MERS-CoV antibody ELISA titers: performance analysis of serologic tests.\u201d","volume":"36","author":"Ko","year":"2017","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"B16","doi-asserted-by":"publisher","first-page":"105924","DOI":"10.1016\/j.ijantimicag.2020.105924","article-title":"\u201cSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges.\u201d","volume":"55","author":"Lai","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B17","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.1038\/s41467-020-16048-4","article-title":"\u201cNeutralization of SARS-CoV-2 spike pseudotyped virus by recombinant ACE2-Ig.\u201d","volume":"11","author":"Lei","year":"2020","journal-title":"Nat. Commun."},{"key":"B18","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1001\/jama.2020.12607","article-title":"\u201cEffect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial.\u201d","volume":"324","author":"Li","year":"2020","journal-title":"JAMA"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1080\/22221751.2020.1773324","article-title":"\u201cPatterns of IgG and IgM antibody response in COVID-19 patients.\u201d","volume":"9","author":"Liu","year":"2020","journal-title":"Emerg. Microbes Infect."},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.02005-20","article-title":"\u201cSerological Assays Estimate Highly Variable SARS-CoV-2 Neutralizing Antibody Activity in Recovered COVID-19 Patients.\u201d","volume":"58","author":"Luchsinger","year":"2020","journal-title":"J. Clin. Microbiol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"107725","DOI":"10.1016\/j.celrep.2020.107725","article-title":"\u201cCross-reactive Antibody Response between SARS-CoV-2 and SARS-CoV Infections.\u201d","volume":"31","author":"Lv","year":"2020","journal-title":"Cell Rep."},{"key":"B22","doi-asserted-by":"publisher","first-page":"m3327","DOI":"10.1136\/bmj.m3327","article-title":"\u201cCovid-19: US approves emergency use of convalescent plasma despite warnings over lack of evidence.\u201d","volume":"370","author":"Mahase","year":"2020","journal-title":"BMJ"},{"key":"B23","doi-asserted-by":"publisher","first-page":"519","DOI":"10.3390\/pathogens9070519","article-title":"\u201cCoronavirus Disease Pandemic (COVID-19): Challenges and a Global Perspective.\u201d","volume":"9","author":"Malik","year":"2020","journal-title":"Pathogens"},{"key":"B24","doi-asserted-by":"publisher","first-page":"2001754","DOI":"10.2807\/1560-7917.ES.2020.25.45.2001754","article-title":"\u201cConvalescent plasma for COVID-19: male gender, older age and hospitalisation associated with high neutralising antibody levels, England, 22 April to 12 May 2020.\u201d","volume":"25","author":"Mehew","year":"2020","journal-title":"Euro. Surveill."},{"key":"B25","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/j.immuni.2020.04.023","article-title":"\u201cDetection of SARS-CoV-2-Specific Humoral and Cellular Immunity in COVID-19 Convalescent Individuals.\u201d","volume":"52","author":"Ni","year":"2020","journal-title":"Immunity"},{"key":"B26","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1080\/22221751.2020.1743767","article-title":"\u201cEstablishment and validation of a pseudovirus neutralization assay for SARS-CoV-2.\u201d","volume":"9","author":"Nie","year":"2020","journal-title":"Emerg. Microbes Infect."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.3201\/eid2607.200841","article-title":"\u201cSevere Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease Patients.\u201d","volume":"26","author":"Okba","year":"2020","journal-title":"Emerg. Infect. Dis."},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abc8413","article-title":"The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients","volume":"5","author":"Premkumar","year":"2020","journal-title":"Sci. Immunol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/s41586-020-2456-9","article-title":"\u201cConvergent antibody responses to SARS-CoV-2 in convalescent individuals.\u201d","volume":"584","author":"Robbiani","year":"2020","journal-title":"Nature"},{"key":"B30","doi-asserted-by":"publisher","first-page":"102554","DOI":"10.1016\/j.autrev.2020.102554","article-title":"\u201cConvalescent plasma in Covid-19: Possible mechanisms of action.\u201d","volume":"19","author":"Rojas","year":"2020","journal-title":"Autoimmun. Rev."},{"key":"B31","doi-asserted-by":"publisher","first-page":"2066","DOI":"10.1093\/cid\/ciaa523","article-title":"\u201cEarly Detection of Severe Acute Respiratory Syndrome Coronavirus 2 Antibodies as a Serologic Marker of Infection in Patients With Coronavirus Disease 2019.\u201d","volume":"71","author":"Rongqing","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1093\/femspd\/ftaa006","article-title":"\u201cCoronaviruses: a paradigm of new emerging zoonotic diseases.\u201d","volume":"77","author":"Salata","year":"2019","journal-title":"Pathog. Dis."},{"key":"B33","doi-asserted-by":"publisher","first-page":"e0242917","DOI":"10.1371\/journal.pone.0242917","article-title":"\u201cBiodistribution and serologic response in SARS-CoV-2 induced ARDS: A cohort study.\u201d","volume":"15","author":"Schlesinger","year":"2020","journal-title":"PloS One"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1001\/jama.2020.4783","article-title":"\u201cTreatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma.\u201d","volume":"323","author":"Shen","year":"2020","journal-title":"JAMA"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1126\/science.abd4250","article-title":"\u201cViral epitope profiling of COVID-19 patients reveals cross-reactivity and correlates of severity.\u201d","volume":"370","author":"Shrock","year":"2020","journal-title":"Science"},{"key":"B36","doi-asserted-by":"publisher","first-page":"24596","DOI":"10.18632\/aging.202362","article-title":"\u201cDynamic monitoring of immune function indexes in COVID-19 patients.\u201d","volume":"12","author":"Song","year":"2020","journal-title":"Aging (Albany NY)"},{"key":"B37","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/S1473-3099(20)30196-1","article-title":"\u201cTemporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study.\u201d","volume":"20","author":"To","year":"2020","journal-title":"Lancet Infect. Dis."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1016\/j.cell.2020.02.058","article-title":"\u201cStructure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein.\u201d","volume":"183","author":"Walls","year":"2020","journal-title":"Cell"},{"key":"B39","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1089\/dna.2005.24.521","article-title":"\u201cProfiles of IgG antibodies to nucleocapsid and spike proteins of the SARS-associated coronavirus in SARS patients.\u201d","volume":"24","author":"Wang","year":"2005","journal-title":"DNA Cell Biol."},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa1143","article-title":"\u201cLongitudinal dynamics of the neutralizing antibody response to SARS-CoV-2 infection.\u201d","author":"Wang","year":"2020","journal-title":"Clin. Infect. Dis"},{"key":"B41","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1038\/s41586-020-2599-8","article-title":"\u201cA vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity.\u201d","volume":"586","author":"Yang","year":"2020","journal-title":"Nature"}],"container-title":["Frontiers in Cellular and Infection Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2021.650487\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,16]],"date-time":"2021-03-16T06:50:36Z","timestamp":1615877436000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2021.650487\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,16]]},"references-count":41,"alternative-id":["10.3389\/fcimb.2021.650487"],"URL":"https:\/\/doi.org\/10.3389\/fcimb.2021.650487","relation":{},"ISSN":["2235-2988"],"issn-type":[{"value":"2235-2988","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,16]]},"article-number":"650487"}}